Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case–control study

• DOI: 10.1007/s13402-010-0006-4
• Publication Date: 2011-02-16T21:39:06Z
• Authors: Monique M. Gerrits; Min Chen; Myrte Theeuwes; Herman van Dekken; Marjolein Sikkema; Ewout W. Steyerberg; Hester F. Lingsma; Peter D. Siersema; Bing Xia; Johannes G. Kusters; C. Janneke van de...; Ernst J. Kuipers
• Keywords: Inflammatory Bowel Diseases

Regular colonoscopic surveillance for detection of dysplasia is recommended in longstanding inflammatory bowel disease (IBD), however, its sensitivity disputed. Screening accuracy may increase by using a biomarker-based strategy.A case-control study was performed to determine the prognostic value DNA ploidy and p53 IBD-related neoplasia. Cases with colorectal cancer (CRC), detected our program between 1985-2008, were selected matched two controls, age, gender, characteristics, interval follow-up, PSC, previous surgery. Biopsies assessed ploidy, p53, grade inflammation Progression neoplasia analyzed Cox regression analysis, adjusting potentially confounding variables.Adjusting we found statistically significant Hazard ratios (HR) development CRC, low (HR5.5; 95%CI 2.6-11.5), abnormal (DNA index (DI) 1.06-1.34, HR4.7; 2.9-7.8 DI>1.34, HR6.6; 3.7-11.7) immunopositivity (HR3.0; 1.9-4.7) over time. When all confounders, (DI 2.7-7.9 HR5.0; 2.5-10.0) (HR1.7; 1.0-3.1) remained predictive neoplasia.In IBD, are important risk factors developing CRC. The yield adding these biomarkers routine assessment biopsies.